Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GSK announces anti-infective drug alliance with Galapagos

GSK announces anti-infective drug alliance with Galapagos

12th December 2007

GlaxoSmithKline (GSK) has announced the formation of a multi-year strategic alliance with Galapagos NV to develop anti-infective drug candidates.

The collaboration will see GSK’s Infectious Diseases Centre for Excellence for Drug Discovery (ID CEDD) work with Galapagos’ natural product drug discovery platform.

Galapagos will be responsible for the discovery and development of the drug candidates through to clinical Proof of Concept, at which stage, GSK will have the option to license the compounds for further development and commercialisation worldwide.

The agreement will see Galapagos receive total technology access fees of up to 3.5 million euros (2.5 million pounds) as well as being eligible to receive 95 million euros in upfront fees, development and regulatory milestone payments for the candidates.

Zhi Hong, senior vice-president and head of GSK’s ID CEDD, confirmed that the company recognised the significant unmet medical need for anti-infective drugs.

“We are confident this new alliance based on natural products will contribute to the advancement of our drug discovery and development programmes in infectious diseases,” he commented.

Onno van de Stolpe, Galapagos’ chief executive officer, welcomed the agreement and indicated that the alliance fitted with the company’s strategy of executing risk / reward sharing deals with big pharmaceutical companies.

Also this week, GSK signed a partnership agreement with OncoMed Pharmaceuticals for the discovery, development and commercialisation of innovative antibody therapeutics for the targeting of cancer stem cells.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.